KaloBios Continues KB001-A Trial For Pseudomonas Aeruginosa Infection in Cystic Fibrosis, Despite Dissolution of Sanofi Licensing Deal
San Francisco based KaloBios Pharmaceuticals, Inc. on Monday released an update on the status of its KB001-A monoclonal antibody development program, including news that multinational Sanofi Pasteur, which had been collaborating with Kalobios on the KB001-A R&D program, is pulling out of the partnership. KaloBios will regain all…